Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Lexicon Pharmaceuticals clinical trials
Also known as Lexicon Genetics.
Part of Invus, L.P. and affiliated entities, which holds 50.6% as of 2026-04-30. Source
The registry lists 61 studies whose lead sponsor is Lexicon Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 26, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Lexicon Pharmaceuticals.
- Lexicon Pharmaceuticals61 studiesSame company
Something wrong?
Focus areas
Conditions Lexicon Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 61. Browse all 61 →
- A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyActive, not recruitingNCT06481891Phase 3
- Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaCompletedNCT04662281Phase 2
- A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)CompletedNCT06203002Phase 2
- Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainCompletedNCT04455633Phase 2
- Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTerminatedNCT03315143Phase 3
- Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TerminatedNCT03521934Phase 3
- Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminatedNCT03386344Phase 3
- A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompletedNCT03242018Phase 3
- Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompletedNCT03242252Phase 3
- Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompletedNCT02926937Phase 3
- Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompletedNCT03285594Phase 3
- Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompletedNCT03066830Phase 3
- Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompletedNCT02926950Phase 3
- Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompletedNCT03332771Phase 3
- Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTerminatedNCT03292653Phase 2
- Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedNCT03351478Phase 3
- Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCompletedNCT02383940Phase 2
- A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCompletedNCT02531035Phase 3
- Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02421510Phase 3
- Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02384941Phase 3
- Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCompletedNCT01742208Phase 2
- Dose-ranging Study in Patients With Type 1 Diabetes MellitusCompletedNCT02459899Phase 2
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedNCT02026063Phase 3
- A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT01456052Phase 2
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2
- Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionCompletedNCT02647918Phase 1
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2
- Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentCompletedNCT03423446Phase 1
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCompletedNCT03302845Phase 1
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3
- Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3
- PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentCompletedNCT02471274Phase 1
- Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsCompletedNCT02195635Phase 1
- Oral Contraceptive DDI StudyStatus unknownNCT02494609Phase 1
- Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsCompletedNCT02373046Phase 1
- Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01528111Phase 1/2
- DDI Study With Multiple-dose LX4211 and Single Dose DigoxinCompletedNCT02300350Phase 1
- DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinCompletedNCT02300363Phase 1
- A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel SyndromeCompletedNCT01494233Phase 2
- Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCompletedNCT01376557Phase 2
- An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsCompletedNCT02157558Phase 1
- A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy SubjectsCompletedNCT02147808Phase 1
- An Open-Label Food Effect Study of Telotristat EtiprateCompletedNCT02157584Phase 1
- A Thorough QT Study of Telotristat EtiprateCompletedNCT02155205Phase 1
- Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCompletedNCT01916863Phase 1
- Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsCompletedNCT01916850Phase 1
- Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsCompletedNCT01913002Phase 1
- An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in MalesCompletedNCT01932528Phase 1
- Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCompletedNCT01555008Phase 1
- Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsCompletedNCT01818232Phase 1